One of the best sci-fi TV shows on Apple TV+ now has a release date
No streamer puts out more quality sci-fi TV shows than Apple TV+. This summer marks the arrival of Foundation season 3, a sci-fi series based on Isaac Asimov's award-winning stories. The streamer unveiled the first teaser and release date for season 3, which continues the show's propensity for expansive world-building and stunning visuals.
'War is upon us,' Hari Seldon (Jared Harris) says in the teaser. Set 152 years after the second season, season 3 picks up with a diminished Cleonic Dynasty and a more established Foundation. The two powers must align in their fight against The Mule (Pilou Asbæk), a ruthless warlord who plans to rule the universe through force and mind control. With so many moving pieces, Apple TV+ describes the upcoming season as a 'deadly game of intergalactic chess.'
Season 3's returning cast includes Harris as Hari Seldon, Lee Pace as Brother Day, Lou Llobell as Gaal Dornick, Cassian Bilton as Brother Dawn, Terrence Mann as Brother Dusk, Laura Birn as Demerzel, Leah Harvey as Salvor Hardin, and Rowena King as Kalle.
Season 3's new additions are Asbæk, Cherry Jones, Brandon P. Bell, Synnøve Karlsen, Cody Fern, Tómas Lemarquis, Alexander Siddig, and Academy Award winner Troy Kotsur.
Foundation stems from executive producer David S. Goyer, a screenwriter best known for his work in two trilogies: Blade and The Dark Knight. Skydance Television produces Foundation for Apple.
Foundation is one of many popular sci-fi TV shows on Apple TV+. Severance is currently the most-watched show on Apple TV+ and one of the frontrunners to win in the dramatic categories at the 2025 Emmys. Silo, For All Mankind, Dark Matter, Invasion, and See are all sci-fi Apple shows that have aired multiple seasons.
Foundation season 3 premieres with one episode on Friday, July 11, on Apple TV+. New episodes will be released weekly every Friday through September 12.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
44 minutes ago
- Forbes
10 Pride-Inspired Cocktails To Make At Home This June
Celebrity Pride with these cocktails perfect for the occasion. The month of June is known as Pride Month. During this month, we take the time to celebrate and honor LGBTQ Pride, and the support the lesbian, gay, bisexual, transgender and queer community. One way that many restaurants and bars around the country are honoring the community this year is creating Pride-inspired cocktails in honor of this month of recognition, and those who stop in these spots can try the beautiful and colorful cocktails, often also donating money to related causes in the process. But an added value of these bright and celebratory cocktails around the nation is that they just may give many of us inspiration for some fun Pride-inspired cocktails to create at home all month long. You'll notice a lot of the Pride-inspired cocktails on this list are bright and full of color – much like a rainbow, which is a symbol of Pride as well. They are also often very festive and fun, perhaps with floral or glitter adornment. These Pride-inspired cocktails will run the gamut as there's many colors in a rainbow, and ingredients in a cocktail but you'll often find these are sweet cocktails with bright colors and seasonal fruits and flavors, with some edible glitter for good measure. Many of these Pride-inspired cocktails go well with a fun and festive gathering or party, which is a big part of appreciating and celebrating Pride month. Absolutely Fabulous This is a super vibrant and herbaceous cocktail made with KLEOS Mastiha Spirit, smooth vodka, lemon juice, simple syrup, and juicy raspberries. Effie Panagopoulos, founder of KLEOS Mastiha Spirit says: 'We launched KLEOS Mastiha Spirit in 2017 at the #1 gay vacation destination on the planet – Mykonos – via a party at the island's gay club, JackieO' Mykonos Town Bar, with fashion icon Patricia Field and this cocktail was made for that party.' Who would enjoy this Pride-inspired cocktail? Anyone who loves a classic Cosmopolitan of the SATC era, or just to have a good time! Petal Pride Pop (Triple P) at Four Seasons Resort Rancho Encantado Santa Fe. Available throughout June in honor of Pride Month at Terra Bar at Four Seasons Resort Rancho Encantado Santa Fe, this handcrafted cocktail is made with vodka, white cranberry, lime juice and Cointreau, topped with a colorful flower encased in an ice mold. Additionally, 25 percent of the proceeds from each drink sold will be directed to the Santa Fe Human Rights Alliance (HRA) in support of the LGBTQ+ community. Food & Beverage Manager Zach Fieder says: 'The edible flower in an ice mold gives our 'white cosmo' a pop of color. This drink is great for EVERYONE! It's fun like a cosmo, but strong enough to pack a punch.' Banana Hammock at Odie B's in Denver. At Odie B's in Denver, this cheeky Pride-inspired cocktail brings all the tropical vibes with rum, lime, banana liqueur and cinnamon. "While a banana hammock may not be for everyone this one really fills out our party cup. Stay fab yall!" said Cliff Blauvelt, owner. PS I Love You at Poka Lola Social Club in Denver. At Poka Lola Social Club in Denver, The PS I Love You is made with Grey Goose Vodka, passion fruit, vanilla bean, and lime, and served in a coupe glass. All throughout June, $1 of each cocktail sold will be donated to Free Mom Hugs. 'Our PS I Love You is really a multifaceted cocktail with the warmth and nostalgia of vanilla bean, the sophistication of Grey Goose and the sweetness of passion fruit,' said Lexi Parker, Beverage Manager of Poka Lola Social Club. The Glam Tini at Michael Jordans Steakhouse. At Michael Jordans Steakhouse located inside the InterContinental Chicago Magnificent Mile Hotel, this Pride-inspired cocktail is made with Absolut Vodka, grapefruit, lemon, and a sprinkle of edible glitter for that perfect touch of sparkle. Open Mic at Four Seasons Hotel Las Vegas. At Four Seasons Hotel Las Vegas, this Pride-inspired cocktail is made with Tito's Vodka, watermelon juice, lemon juice, a splash of Fever-Tree Sparkling Lime & Yuzu, and is finished with a mint sprig garnish. Open Mic was created in tribute to Las Vegas's drag performers, poets, musicians, and artists. A portion of proceeds from each Open Mic cocktail sold will benefit The LGBTQ+ Center of Southern Nevada. Lexi Panis, Beverage Manager, says: 'With Open Mic, we wanted to create a cocktail that not only celebrates individuality but also sparks conversation. The choice of fresh watermelon was intentional—it's bright and refreshing, a perfect fit for summer and a nod to creativity. We're proud to offer something vibrant and full of heart, all while supporting a vital local cause.' Yuzu Belong to Me at Bar Collins at Loews Miami Beach Hotel South Beach. Found at Bar Collins at Loews Miami Beach Hotel in South Beach, this is a playful, non-alcoholic blend of lychee, yuzu, raspberry and yuzu soda with a rainbow gummy bear garnish. Assistant Director of Food & Beverage at Loews Miami Beach Hotel, Lucas Scudeler, says, 'This non-alcoholic drink from our Free Spirited beverage program is perfect for all ages to enjoy this Pride Month. Bright and bold with flavor, it's refreshingly tart, with a name that represents belonging and love.' In My Nature at 1 Hotels. The color violet is a known symbol of LGBTQIA+ pride and solidarity—and in tribute to that, this cocktail at 1 Hotels blends butterfly pea flower and elderflower. 'With In My Nature, we wanted something that felt seasonal, intentional, and full of pride. The violet hue, thanks to butterfly pea and elderflower, nods to both nature and the LGBTQIA+ spirit. It's light and rooted in meaning. This cocktail is a great way to give back to deserving communities that continue to inspire us," said Steven Minor, Corporate Beverage Director at Starwood Hotels. Pride & Passion at Top of the Mark at InterContinental Mark Hopkins in San Francisco. At Top of the Mark at InterContinental Mark Hopkins in San Francisco, Pride & Passion was crafted in honor of Pride month, combinging smooth bourbon, passionfruit, the subtle spice of Falernum, basil and ginger veer. Furthmore, $3 of each cocktail purchased donated to the SF LGBT Center. The Pride of Aqua at Aqua New York. At Aqua New York, The Pride of Aqua is a colorful blend of Weber Ranch Vodka, Novo Fogo Cachaca, coconut, pineapple, and a hint of lime, nodding to Pride month. Throughout June, 20% of the proceeds will be donated to Lambda Legal, a civil rights organization focusing on the LGBTQ+ community. 'With the Pride of Aqua, we wanted to create a cocktail that captures the vibrant spirit of Pride-colorful, bold, and celebratory", says Alejandro Marquina, Beverage Director at Aqua New York. 'The combination of Weber Ranch Vodka, Novo Fogo Cachaça, coconut, pineapple, and lime delivers a bright, tropical profile.' And if you have room for dessert after all those Pride-inspired cocktails… Pride Pancakes at Snooze. In honor of Pride Month, Snooze created bright and colorful Pride pancakes that just may be exactly what the doctor ordered after enjoying a few Pride-inspired cocktails. This dish is made up of buttermilk pancakes that are filled with white chocolate chips and all-natural rainbow sprinkles, topped with sweet cream drizzle, whipped mascarpone and, of course, more sprinkles and will be available at all 70 Snooze locations nationwide throughout the month of June.
Gizmodo
an hour ago
- Gizmodo
New Russian Satellite Appears to Be Stalking U.S. Satellite in Orbit
A recently launched Russian satellite is getting uncomfortably cozy with a U.S. reconnaissance satellite, leading Space Command to worry that it's part of an anti-satellite weapon being deployed to orbit. Cosmos 2588 launched on May 23 to a near-circular orbit, placing it eerily close to a U.S. reconnaissance satellite, USA 338. The move prompted suspicion that it's an attempt by Russia to deliberately stalk the U.S. government satellite. This isn't the first time Russia has deployed a sneaky satellite to trail behind and allegedly observe another satellite in orbit, but this time it may be connected to Russia's controversial anti-satellite program. 'U.S. Space Command can confirm Russia's recent launch put a Russian satellite into an orbit near a U.S. government satellite,' a Space Command spokesperson is quoted as saying to Breaking Defense. 'Russia continues to research, develop, test, and deploy a suite of counter space systems that threaten the safety and the stability of the domain, so consistent with all on-orbit objects, USSPACECOM will continue to monitor for concerning behavior or activity related to this launch.' Slingshot Aerospace reports that the alleged spy satellite, Cosmos 2588, is a NIVELIR military inspection satellite likely carrying a kinetic weapon onboard. Its alignment with USA 338 'strongly suggests COSMOS 2588 may be actively monitoring or 'chasing' it,' the satellite tracking company wrote in a statement. Slingshot Aerospace has been tracking the two satellites, revealing that Cosmos 2588 is orbiting at a slightly higher altitude and that the two objects will have a close flyby of one another roughly every four days. The two satellites come as close as 62 miles (100 kilometers) from one another, Marco Langbroek, an astronomer and expert on space situational awareness at the Delft University of Technology in the Netherlands, wrote on X. Not much else is known about USA 338 as it doesn't have publicly available orbital data, but it is believed to be a part of the National Reconnaissance Office's KH-series electro-optical surveillance network, known as the Crystal constellation, according to Interesting Engineering. This isn't the first time Russia has allegedly deployed a satellite for such a purpose. In April 2023, a Russian satellite appeared to be closely trailing a classified U.S. military satellite, and Russia's Kosmos 2558, launched in August 2022, was deployed into the same orbital plane as a U.S. military satellite, dubbed USA 326. In 2020, another Russian satellite, Kosmos 2542, stalked USA 245, an electro-optical spy satellite in low Earth orbit. The U.S. isn't completely innocent either. In June 2017, classified U.S. military satellite USA 276 snuck up on the International Space Station at a close distance of about 4 miles (6.4 kilometers). Earlier in 1998, hobbyists discovered a U.S. satellite that was believed to have been used for space spying purposes as well. Russia's satellites, however, are believed to be part of the country's efforts to develop an anti-satellite weapon designed to destroy other objects in space. In November 2021, Russia destroyed a defunct Soviet-era satellite in low Earth orbit, producing thousands of pieces of orbital debris. The test prompted the United Nations to draft a resolution against tests of anti-satellite (ASAT) missile systems, which was led by the Biden administration after the U.S. adopted a self-imposed ban on ASAT tests. A total of 155 countries voted in favor of the resolution, while nine voted against it, including Russia, China, Cuba, Syria, and Iran. 'This is the fourth time in five years that they launch a satellite into a coplanar orbit with a US optical reconnaissance satellite,' Langbroek wrote on X. 'So no, not mere coincidence but deliberate.'
Medscape
an hour ago
- Medscape
Fact or Fiction: Ovarian Cancer and Drug Resistance
In ovarian cancer, the emergence of drug resistance has been shown to limit the durability of therapeutic treatment benefit and contribute substantially to ovarian cancer's high mortality rate. Factors such as treatment-free intervals and tumor microevolution may allow for re-sensitization to platinum agents in select patients. In addition to tumor biology, the tumor microenvironment plays a pivotal role in therapeutic resistance. Targeted therapies, once heralded as a solution to chemotherapy resistance, have been shown to face similar obstacles. Drug resistance in ovarian cancer management is an ongoing field of study as clinicians look to limit its impact improve outcomes. Platinum resistance in ovarian cancer is not always permanent. While many patients relapse with tumors less responsive to platinum-based chemotherapy, resistance can be dynamic. Mechanisms such as epigenetic alterations, modulation of DNA damage response, and temporary activation of drug efflux pumps may contribute to reversible resistance. Importantly, a subset of patients initially labeled as platinum-resistant may benefit from platinum rechallenge after a treatment-free interval, particularly if newer maintenance strategies or resensitizing agents are used. This has led to the concept of a "platinum-free interval" to help guide re-treatment. Understanding these nuances is crucial for tailoring treatment strategies and optimizing outcomes. Learn more about medications used in ovarian cancer. While HRD — often due to BRCA1/2 mutations — initially predicts strong sensitivity to DNA-damaging therapies like platinum agents and PARP inhibitors, resistance commonly emerges over time. A key mechanism is the restoration of homologous recombination through secondary or "reversion" mutations in HR pathway genes. These mutations enable tumor cells to resume high-fidelity DNA repair, diminishing the cytotoxic effects of therapy. Additionally, tumors may activate compensatory pathways such as non-homologous end joining or increase drug efflux activity. This resistance may not be detectable at diagnosis and can evolve under therapeutic pressure. Consequently, current research emphasizes longitudinal molecular monitoring to capture evolving resistance mechanisms. Clinically, this underscores the need for re-biopsy or circulating tumor DNA analysis to reassess HR status in recurrent disease, which may influence therapy selection. Learn more about the importance of biopsy in ovarian cancer. Tumor heterogeneity — both genetic and phenotypic — plays a central role in drug resistance and further complications treatment outcomes. Ovarian tumors often consist of diverse subclonal populations, some of which may possess innate resistance traits. Within a single ovarian tumor, multiple subclonal populations may coexist, each with distinct characteristics and sensitivity profiles. When systemic therapy is applied, sensitive clones are eliminated, but resistant ones may persist and expand. Single-cell and spatial transcriptomics studies have mapped how this clonal evolution occurs, revealing that treatment can select for resistant subpopulations not evident at baseline. Heterogeneity also affects the tumor microenvironment and immune response, further complicating therapeutic strategies. Clinically, this variability can manifest as mixed responses, where some lesions regress while others progress. Addressing heterogeneity remains a major challenge and has sparked interest in combination therapies and adaptive trial designs. Personalized treatment strategies based on real-time tumor profiling are likely to improve outcomes by accounting for this complexity. Learn more about ovarian cancer guidelines. Targeted therapies are susceptible to various resistance mechanisms, many of which overlap with those seen in chemotherapy. For example, resistance to PARP inhibitors, widely used in HRD-positive ovarian cancers, can arise from secondary mutations restoring DNA repair function or through enhanced drug efflux. Similarly, resistance to angiogenesis inhibitors may develop via upregulation of alternative pro-angiogenic pathways or changes in tumor vasculature that circumvent the need for VEGF signaling. Resistance is further complicated by factors such as epigenetic reprogramming and altered cell signaling networks. These findings have led to interest in combining targeted agents with immune checkpoint inhibitors, DNA repair modulators, or epigenetic therapies to overcome resistance. Future success with targeted therapy will likely depend on combination approaches informed by tumor genomics and adaptive resistance profiling. Learn more about risk assessment and genetic counseling in ovarian cancer. The tumor microenvironment (TME) is a key contributor to drug resistance in ovarian cancer. Immune cells such as regulatory T cells and tumor-associated macrophages (TAMs) create an immunosuppressive milieu that hinders effective therapy. Additionally, fibroblasts and extracellular matrix components can form physical barriers that limit drug penetration. Cytokines and growth factors secreted within the TME also modulate signaling pathways in tumor cells, promoting survival and resistance. Studies have shown that high TAM density is associated with poor response to both chemotherapy and immunotherapy, and interventions targeting the TME may help reverse resistance. This includes strategies like macrophage reprogramming, TME remodeling agents, and stromal-targeting therapies. Incorporating TME characteristics into clinical decision-making may help guide therapeutic combinations and predict response. Learn more about tumor biomarkers in ovarian cancer.
